￥ 人民币 $ USD € 欧元
简体中文 English 繁体中文
Menu

Oncology

Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
What is the effect of Rybrevant, the first targeted therapy for difficult-to-treat lung cancer?

2025-10-19 11:44:20

Check Details
Rybrevant targeted drug, the latest lung cancer drug approved for marketing?

2025-10-19 11:44:20

Check Details
When will Lumakras (sotorasib) be available in China? What disease is treated?

2025-10-19 11:44:20

Check Details
What kind of people are suitable for using Lumakras? What are the precautions for using Lumakras

2025-10-19 11:44:20

Check Details
[News Flash] Lumakras, the first KRAS-targeting drug for lung cancer, is approved by the FDA for marketing

2025-10-19 11:44:20

Check Details
How much does a box of Lumakras cost in 2021? Where can I buy imported Lumakras cheaper?

2025-10-19 11:44:20

Check Details
How long does it take for resistance to icotinib to develop? What are the symptoms of icotinib resistance?

2025-10-19 11:44:20

Check Details
How much does a box of the new lung cancer drug Icotinib cost? Can the targeted drug icotinib be purchased in domestic pharmacies?

2025-10-19 11:44:20

Check Details
Nivolumab/ipilimumab combination chemotherapy can treat advanced non-small cell lung cancer

2025-10-19 11:44:20

Check Details
CLN-081 shows anti-tumor activity in first-in-human trial for treatment of mutation-positive non-small cell lung cancer_Canghule

2025-10-19 11:44:20

Check Details
Rybrevant, the first targeted therapy for refractory lung cancer, is here

2025-10-19 11:44:20

Check Details
Rybrevant, a new drug for non-small cell lung cancer, was approved for marketing, and when Rybrevant will be launched

2025-10-19 11:44:20

Check Details
Category
相关知识